NoneNot only does the Taylor Swift tour create a temporary surge in economic activity, but it also leaves a lasting impact on the local communities. The exposure generated by hosting such massive concerts helps put these cities on the map, attracting future tourists and driving further economic growth. The buzz and excitement surrounding the events create a sense of energy and vitality that lingers long after the final notes of the concert have faded away.Lobbying intensifies for vacant CS positionsIn a stunning upset at the recent championship match, Dragon Rise Huang emerged victorious over the defending champion, sparking a wave of excitement and anticipation among fans and pundits alike. Following his impressive win, Dragon Rise Huang sat down for an exclusive post-match interview to reflect on his journey to success and his aspirations for the future.
None
NoneIn the midst of this uncertainty, one thing is clear: in the world of A-share markets, anything can happen, and everything can change in an instant. Investors must remain vigilant and adaptable, ready to respond to new developments and adjust their strategies accordingly. As the three major signals continue to flash and the market sentiment continues to shift, one thing is certain: in the A-share market, one must always expect the unexpected.
In response to the incident, the Civil Aviation Administration of China (CAAC) has also issued a statement urging airlines to review and reinforce their protocols for handling medical emergencies and ensuring the safety of passengers during flights. The CAAC has emphasized the importance of having adequate medical supplies and personnel on board to address emergencies promptly and effectively.None
THOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE AmgenScientist reveals 'cyborg' technology that controls insects' movements
CHICAGO — The Seattle Seahawks placed running back Kenneth Walker III on injured reserve prior to their game against the Chicago Bears on Thursday because of an ankle injury. Walker hurt his ankle in last week’s loss to Minnesota and left that game after sitting out the previous two because of a calf problem. He also missed two weeks in September with an oblique issue. Walker has run for 573 yards and seven touchdowns on 153 carries. A second-round draft pick by Seattle in 2022, he has 2,528 yards rushing and 24 TDs in his career. Walker could, in theory, return if the Seahawks win two playoff games, though their postseason hopes were slim entering the game against Chicago. Seattle (8-7) trailed the NFC West-leading Los Angeles Rams (9-6) by one game with two to play. The Seahawks’ best path to the postseason was to win the final two regular-season games and have Los Angeles lose to Arizona on Saturday. Seattle visits the Rams to close the regular season. With Walker out, Seattle signed rookie running back George Holani off the practice squad.In conclusion, Justin Trudeau's response to President Trump's tariffs demonstrates his commitment to protecting Canadian interests and standing up for Canadian workers. By implementing retaliatory tariffs, working with other nations, engaging in diplomatic dialogue, and diversifying Canada's trade relationships, Trudeau is taking a multi-faceted approach to address the challenges posed by the U.S. tariffs. With a combination of resilience, determination, and strategic planning, Trudeau is preparing Canada for the road ahead and ensuring that Canadian industries and workers are not left vulnerable to external pressures.
Title: "The Blues' Return to Title Contention? Mahrez Gives Chelsea Fans the Courage to ‘Dream’"
Karine Jean-Pierre refuses to apologize for saying Biden wouldn't pardon Hunter as she's asked why anyone should believe the presidentInitially, the excitement was palpable as users navigated the sleek interface and explored the unique features of the website. Social media buzzed with chatter about the launch, drawing in curious newcomers by the minute. However, as the influx of traffic grew exponentially, the server struggled to keep up with the unprecedented demand.
As the first half progressed, Munios began to find their rhythm and started to create opportunities of their own. The midfield duo of Rodriguez and Sanchez were instrumental in controlling the flow of the game, distributing the ball effectively and launching dangerous counterattacks. It was Rodriguez who eventually broke the deadlock with a stunning long-range strike that sent the home fans into a frenzy.
The role of a sporting director is crucial in today's era of football, as it involves overseeing the club's sporting strategy, player recruitment, and contract negotiations. By not appointing a sporting director, Manchester United are signaling a shift in their approach to managing the footballing side of the club.
Title: Evan Kyle's Love Affair with Chinese Cuisine: A Culinary Exploration on His TravelsGerry Dulac: Steelers defense failed to close out a win — again
In addition to the individual competitions, the Milan Winter Olympics will also feature team events and relays, adding an extra layer of excitement to the games. Athletes from around the world will come together to showcase their talent and determination, with each competition area offering its own unique blend of challenges and thrills.How many reserve planes are typically lying around in airlines? Not many. Airlines can't function like the Air Force and have numerous expensive jets lying around "just in case." Still, aircraft breakdown and mishaps happen while political/weather/other factors may ground their aircraft. Airlines are also called on to perform rescue flights when a crisis breaks out (these aircraft need to be pulled form somewhere). In these situations, airlines may need to call on another aircraft—but do they have reserve planes lying around? A minimum number of spare planes There isn't much information about how many aircraft an airline keeps as spares. The number of available aircraft that can be called on (or pulled from other operations) is likely to be higher in the winter/low season periods. In the peak season, the airline may not have many "spare" aircraft at all. In 2018, the blog From the Holocron wrote that US Airways (now emerged with American Airlines ) stated it had around 13 planes in reserve. "Since we operate a “different” schedule each day the number fluctuates a bit. Today for instance, we currently have 340 active lines of flying on the mainline operation. Here is what we have built into the schedule for spares: 13 spares total.... 2 737’s (covering 300s and 400s), 7 Airbus (covering 319/320/321), 2 B757 (covering 757/767), 1 A330 (covering A330-200 and 300) and 1 EMB 190." - US Airlines (reported by Crankyflier in 2012) In fact, according to US Airlines' answer, the airline kept more or less one spare aircraft for each fleet type available. US Airlines spare aircraft in 2012: Quantity: Boeing 737: 2 Airbus A319/320/321: 7 Boeing 757: 2 Airbus A330: 1 EMB 190: 1 Total: 13 Aircraft are phenomenally expensive to purchase, operate, and maintain (even if they are just sitting on the tarmac). No airline wants to have billions invested in aircraft sitting around, not generating income. Therefore, airlines strive to keep their reserve fleets as low as possible and their fleets as active and productive as possible. Airlines operate on very tight profit margins, and keeping many reserve aircraft is not viable. Airlines may have comparatively more widebody aircraft as "spares" as the pain of cancelation for those flights is typically higher. Airlines keep certain spare parts for their aircraft on hand so that many can be quickly repaired. It should also be noted that aircraft maintenance is preventative maintenance—no airline wants to fix an aircraft after it breaks; they want to fix it before it breaks. Russia's grounded A320neo/A321neos Russia is in a unique position as it is under international sanctions and is unable to purchase new aircraft to buy the spare parts it needs to maintain its existing Airbus and Boeing fleets (although it does possess considerable ability to keep them flying). Russia is apparently particularly struggling to maintain the new CFM International LEAP engines found on its Airbus A320neo/A321neo fleets. Reportedly, half of its Airbus neos are now grounded, and half of that number is not expected to fly again. The other half are grounded as "spares" of sorts to preserve their remaining engine life and be put back in service during the peak season when they are more needed. The aircraft in question was most likely delivered to Moscow on February 24. Chartered aircraft are an option Sometimes, an aircraft is forced to make an emergency landing in a remote airfield, leaving the passengers stranded. An example of that is in 2017 when Air France Flight 066 Airbus A380 suffered an engine blowout and had to make an emergency landing in a remote military airfield in Newfoundland. Air France had to send rescue aircraft to transport its stranded passengers. That Air France incident shows another option airlines have - charter an aircraft. The Airbus A380 is the largest capacity passenger aircraft flying today, so no aircraft (short of another Airbus A380 ) has the capacity to pick up all of an A380's passengers (assuming it was full). The Air France A380 was carrying 520 people - 496 passengers and 24 crew). The passengers on the A380 were not permitted to deplane, so time was of the essence to get them another ride. Air France dispatched two aircraft to pick up the passengers and crew - an Air France Boeing 777 and a chartered Boeing 737. It is unclear which company Air France charted the Boeing 737 from. Government rescue operations and rival airlines' relief fares can both help. Having flexibility built into the system Airlines may have some flexibility in having redundancy built into their flight operations. Airlines can increase the number of flights that run between hubs so that many flights have extra seats available. If airplanes are not full, then it may be easier to accommodate passengers if a flight is canceled (or pull an aircraft from that route). For example, if there are five flights a day from Los Angeles to NYC and one is canceled, the other flights may have enough slack to accommodate them. Alternatively, say a flight from Atlanta to Portland is canceled. The airline may be able to move the passengers on other alternative routes (e.g., Atlanta to San Francisco connecting to Portland). Example alternatives to having spare planes: Chartering an airplane Pulling an airplane from a route Loading passengers on alternative flights The big issue here is that airlines don't want to be flying half-empty planes either. Still, there are benefits to having airplanes that are not completely full and having more than one possible way to route passengers to their end destinations. Flexibility can be further enhanced by having codeshare agreements with other airlines. For example, one passenger had a Qatar Airlines flight from Cape Town, South Africa, to Yerevan, Armenia, via Qatar. Qatar's Cape Town flight was canceled, so the passenger was transferred to a British Airways flight from Cape Town to London, where he changed to a Qatar flight to Doha and then to Yerevan.